Navigate Fool.com
Will INO beat
the market?

Inovio Biomedical Corp. (NYSEMKT: INO)

Community Rating: 2 Stars: Unattractive

12.98 -0.12 (-0.92%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.92
Previous Close $13.10
Daily Range $12.43 - $13.40
52-Week Range $4.88 - $15.80
Market Cap $780.8M
P/E Ratio -9.36
Dividend (Yield) $0.00 (0.0%)
Volume 3,596,946
Average Daily Volume 2,032,791
Current FY EPS -$0.71

How do you think INO
will perform against the market?

Top INO Bull/Bear Pitches


ColossalSlug (2.24)
Submitted March 13, 2014

Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the busin … More

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted August 16, 2013

Letting go of a green thumb on a tiny biopharma that's turned itself into a sudden multibagger is always a tough decision. I've dropped out so many times content with a couple of hundred points only t … More

3 Replies Reply Report this Post

News & Commentary

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit

The health care sector saw a flurry of major news yesterday. Here are three key stories that investors may have missed.

Why Inovio Pharmaceuticals Inc Stock Livened Up Today

A phase 2 trial success lifts hope around Wall Street for Inovio's HPV-fighting vaccine VGX-3100

Roundtable: 3 Stocks Janet Yellen Would Hate

The Fed thinks biotech stocks are overvalued. Here's where they're right.

Tuesday Sector Laggards: Biotechnology, Drugs

Why Merck Should Buy Inovio, Seattle Genetics, or MannKind

Merck could be gearing up for an acquisition spree. Could Inovio, Seattle Genetics, and MannKind be potential takeover targets?

5 of Last Week's Biggest Winners

These five stocks posted double-digit percentage gains.

Is Inovio Poised to Climb, or Will It Tumble?

VGX-3100 is a big opportunity for Inovio -- and a big risk.

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

3 Stocks Crushed by the Market This Week

Double-digit declines in just a few days. Here's three of this week's worst health-care stocks.

Are Investors Wrong About Inovio Pharmaceuticals?

Inovio Pharmaceuticals is on the cusp of a pivotal mid-stage data readout. Heading into this event, shorts have been jumping into the stock with both feet. Here's why.

See More INO News...





Inovio Biomedical Corp. (INO) Description

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals. Website: http://www.inovio.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks